Clinical Study of Stent Versus Direct Atherectomy to Treat Iliac Artery Occlusive Diseases
Primary Purpose
Iliac Artery Occlusion
Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
stent
plaque excision system
Sponsored by

About this trial
This is an interventional treatment trial for Iliac Artery Occlusion focused on measuring stent, atherectomy, iliac Artery
Eligibility Criteria
Inclusion Criteria:
- The patients have non thrombotic arteriosclerosis obliterans of the common iliac or external iliac arteries
- Clinical diagnosis of stenosis or occlusive disease
- The patients have unobstructed distal outflow tract
- Receiving surgical treatment at the same time
Exclusion Criteria:
- The patients who have previously implanted stent(s) or stent graft(s) in target leg
- Life expectancy less than 12 months
- Has any planned surgical or endovascular intervention of target vessel 30 days before or after index procedure
- Thrombophlebitis, uremia, or deep venous thrombus, within past 30 days
- Receiving dialysis or immunosuppressant therapy
- Recent stroke within past 90 days
- Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or ticlopidine (Ticlid®), heparin, Nitinol (nickel titanium), contrast agent, that cannot be medically managed
- Tissue loss due to ischemic disease (Rutherford/Becker category 5 or 6)
- Serum creatinine level >/= 2.5 mg/dl at time of screening visit
- Known or suspected active infection at the time of the procedure
- Bleeding diathesis
- Patient is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol.
- Patients are known to be pregnant, incarcerated, mentally incompetent, and/or alcohol or drug abuser.
- Patients are currently participating in any other investigational drug or medical device study that has not completed primary endpoint(s) evaluation or clinically interferes with the endpoints from this study or future participation in such studies prior to the completion of this study.
Sites / Locations
- Yongquan GuRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Stent
Atherectomy
Arm Description
Stent group
Atherectomy group
Outcomes
Primary Outcome Measures
12-month Primary Patency Rate
Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis >50% with a peak systolic velocity ratio >2.4 as measured by Duplex ultrasound.
12-month Limb Salvage Rate
Limb Salvage is defined as the freedom from secondary major amputation
Secondary Outcome Measures
Index Limb Ischemia at 6-month Follow up
Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.
Index Limb Ischemia at 12-month Follow up
Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.
Major Adverse Events at 12-month Post Procedure
Major adverse events included death, index limb ischemia, index limb amputation, clinically driven target lesion revascularization , and significant embolic events, which were defined as causing end-organ damage.
Full Information
NCT ID
NCT04361071
First Posted
December 27, 2017
Last Updated
April 22, 2020
Sponsor
Xuanwu Hospital, Beijing
1. Study Identification
Unique Protocol Identification Number
NCT04361071
Brief Title
Clinical Study of Stent Versus Direct Atherectomy to Treat Iliac Artery Occlusive Diseases
Official Title
Clinical Study of Stent Versus Direct Atherectomy to Treat Iliac Artery Occlusive Diseases
Study Type
Interventional
2. Study Status
Record Verification Date
August 2019
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2018 (Actual)
Primary Completion Date
December 1, 2022 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Xuanwu Hospital, Beijing
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a randomized study comparing stent and plaque excision systems in treatment of Iliac artery occlusive disease.
Detailed Description
This is a randomized study comparing stent and plaque excision systems in treatment of Iliac artery occlusive disease
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Iliac Artery Occlusion
Keywords
stent, atherectomy, iliac Artery
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Stent
Arm Type
Active Comparator
Arm Description
Stent group
Arm Title
Atherectomy
Arm Type
Active Comparator
Arm Description
Atherectomy group
Intervention Type
Device
Intervention Name(s)
stent
Intervention Description
stent
Intervention Type
Device
Intervention Name(s)
plaque excision system
Intervention Description
plaque excision system
Primary Outcome Measure Information:
Title
12-month Primary Patency Rate
Description
Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis >50% with a peak systolic velocity ratio >2.4 as measured by Duplex ultrasound.
Time Frame
12 months
Title
12-month Limb Salvage Rate
Description
Limb Salvage is defined as the freedom from secondary major amputation
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Index Limb Ischemia at 6-month Follow up
Description
Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.
Time Frame
6 months
Title
Index Limb Ischemia at 12-month Follow up
Description
Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.
Time Frame
12 months
Title
Major Adverse Events at 12-month Post Procedure
Description
Major adverse events included death, index limb ischemia, index limb amputation, clinically driven target lesion revascularization , and significant embolic events, which were defined as causing end-organ damage.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The patients have non thrombotic arteriosclerosis obliterans of the common iliac or external iliac arteries
Clinical diagnosis of stenosis or occlusive disease
The patients have unobstructed distal outflow tract
Receiving surgical treatment at the same time
Exclusion Criteria:
The patients who have previously implanted stent(s) or stent graft(s) in target leg
Life expectancy less than 12 months
Has any planned surgical or endovascular intervention of target vessel 30 days before or after index procedure
Thrombophlebitis, uremia, or deep venous thrombus, within past 30 days
Receiving dialysis or immunosuppressant therapy
Recent stroke within past 90 days
Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or ticlopidine (Ticlid®), heparin, Nitinol (nickel titanium), contrast agent, that cannot be medically managed
Tissue loss due to ischemic disease (Rutherford/Becker category 5 or 6)
Serum creatinine level >/= 2.5 mg/dl at time of screening visit
Known or suspected active infection at the time of the procedure
Bleeding diathesis
Patient is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol.
Patients are known to be pregnant, incarcerated, mentally incompetent, and/or alcohol or drug abuser.
Patients are currently participating in any other investigational drug or medical device study that has not completed primary endpoint(s) evaluation or clinically interferes with the endpoints from this study or future participation in such studies prior to the completion of this study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jianming Guo, M.D.
Phone
13146369562
Email
guojianming1020@icloud.com
First Name & Middle Initial & Last Name or Official Title & Degree
Yongquan Gu, M.D.
Phone
15901598209
Email
15901598209@163.com
Facility Information:
Facility Name
Yongquan Gu
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100053
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianming Guo, M.D.
Phone
13146369562
Email
guojianming@icloud.com
First Name & Middle Initial & Last Name & Degree
Yongquan Gu, M.D.
Phone
15901598209
Email
15901598209@163.com
12. IPD Sharing Statement
Learn more about this trial
Clinical Study of Stent Versus Direct Atherectomy to Treat Iliac Artery Occlusive Diseases
We'll reach out to this number within 24 hrs